Literature DB >> 22644636

Outcome of in vitro fertilization in patients with proven poor ovarian responsiveness after early vs. mid-follicular LH exposure: a prospective, randomized, controlled study.

Alberto Revelli1, Alessandra Chiado', Daniela Guidetti, Francesca Bongioanni, Valentina Rovei, Gianluca Gennarelli.   

Abstract

OBJECTIVE: To compare early vs. mid-follicular exposure to LH in patients with poor ovarian responsiveness undergoing in vitro fertilization (IVF).
DESIGN: Prospective, randomized, controlled trial.
SETTING: University Hospital, University-affiliated private Clinic. PATIENTS: Five hundred-thirty women with poor ovarian responsiveness during the first IVF cycle, undergoing their second IVF attempt.
INTERVENTIONS: In a GnRH-analogue long protocol, ovarian stimulation with recombinant FSH (300 IU/day) plus randomly assigned addition of recombinant LH (150 IU/day) from day 1 (early LH exposure; n = 264) or from day 7 (late LH exposure; n = 266). MAIN OUTCOME MEASURE(S): Primary outcome was the number of oocytes retrieved. Secondary outcomes were: cancellation rate, total gonadotropin dose, duration of ovarian stimulation, number of embryos available for transfer, pregnancy rate per started cycle, per OPU and per embryo transfer, implantation rate, delivered/ongoing pregnancy rate.
RESULTS: Apart from the totally administered LH dose, that was significantly higher in the group receiving it from day 1, all parameters related to IVF outcome were non significantly different in the two groups.
CONCLUSIONS: Adding LH to FSH from day 1 or from day 7 of ovarian stimulation in a GnRH-agonist long protocol exerts comparable effects on IVF outcome in poor responders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644636      PMCID: PMC3463670          DOI: 10.1007/s10815-012-9804-0

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  26 in total

Review 1.  Gonadotropic control of ovarian follicular growth and development.

Authors:  S G Hillier
Journal:  Mol Cell Endocrinol       Date:  2001-06-20       Impact factor: 4.102

2.  Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study.

Authors:  J N Hugues; J Soussis; I Calderon; J Balasch; R A Anderson; A Romeu
Journal:  Hum Reprod       Date:  2004-12-23       Impact factor: 6.918

Review 3.  Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles.

Authors:  M H Mochtar; M Ziech; M van Wely
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

4.  Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation.

Authors:  Marco Filicori; Graciela Estela Cognigni; Elena Gamberini; Lodovico Parmegiani; Enzo Troilo; Brunilde Roset
Journal:  Fertil Steril       Date:  2005-08       Impact factor: 7.329

5.  A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates.

Authors:  R Lahoud; M Al-Jefout; J Tyler; J Ryan; G Driscoll
Journal:  Hum Reprod       Date:  2006-06-19       Impact factor: 6.918

6.  Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age.

Authors:  Francisco Fábregues; Montserrat Creus; Joana Peñarrubia; Dolors Manau; Juan A Vanrell; Juan Balasch
Journal:  Fertil Steril       Date:  2006-03-09       Impact factor: 7.329

7.  Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.

Authors:  G De Placido; C Alviggi; A Perino; I Strina; F Lisi; A Fasolino; R De Palo; A Ranieri; N Colacurci; A Mollo
Journal:  Hum Reprod       Date:  2004-12-02       Impact factor: 6.918

8.  Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy.

Authors:  Efstratios M Kolibianakis; Carola Albano; Jarl Kahn; Michel Camus; Herman Tournaye; Andre C Van Steirteghem; Paul Devroey
Journal:  Fertil Steril       Date:  2003-04       Impact factor: 7.329

Review 9.  Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis.

Authors:  E M Kolibianakis; L Kalogeropoulou; G Griesinger; E G Papanikolaou; J Papadimas; J Bontis; B C Tarlatzis
Journal:  Hum Reprod Update       Date:  2007-06-23       Impact factor: 15.610

10.  Ovarian sensitivity index is strongly related to circulating AMH and may be used to predict ovarian response to exogenous gonadotropins in IVF.

Authors:  Valentina Biasoni; Ambra Patriarca; Paola Dalmasso; Angela Bertagna; Chiara Manieri; Chiara Benedetto; Alberto Revelli
Journal:  Reprod Biol Endocrinol       Date:  2011-08-09       Impact factor: 5.211

View more
  4 in total

1.  Analysis of androgen receptor and anti-Müllerian hormone pathways in human granulosa cells under luteinizing hormone treatment.

Authors:  Kuo-Chung Lan; Shiuh Young Chang; Fu-Jen Huang; Hsin-Jung Lin; Ching-Yuang Lin; Ko-En Huang; Hong-Yo Kang
Journal:  Reprod Biol Endocrinol       Date:  2013-02-21       Impact factor: 5.211

2.  Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population.

Authors:  Alberto Revelli; Grazia Pettinau; Gemma Basso; Andrea Carosso; Alessandro Ferrero; Cecilia Dallan; Stefano Canosa; Gianluca Gennarelli; Daniela Guidetti; Claudia Filippini; Chiara Benedetto
Journal:  Reprod Biol Endocrinol       Date:  2015-07-25       Impact factor: 5.211

3.  Controlled ovarian stimulation with r-FSH plus r-LH vs. HMG plus r-FSH in patients candidate for IVF/ICSI cycles: An RCT.

Authors:  Ensieh Shahrokh Tehraninejad; Mina Farshbaf Taghinejad; Batool Hossein Rashidi; Fedyeh Haghollahi
Journal:  Int J Reprod Biomed       Date:  2017-07

4.  A cohort study of both human menopausal gonadotropin (HMG) and recombinant luteinizing hormone addition at early follicular stage in in vitro fertilization outcome: A STROBE-compliant study.

Authors:  Xi Xia; Yu Shi; Lan Geng; Dan Liu; Zhenhui Hou; Hongbo Lin; Rong Li; Haiyan Wang; Liyuan Tao; Fanhua Meng; Jian Da; Yun Chen; Jie Qiao; Weiping Qian; Hongzhen Li
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.